País: Sudáfrica
Idioma: inglés
Fuente: South African Health Products Regulatory Authority (SAHPRA)
Lennon
AZOR-0,25 Tablets AZOR-0,5 Tablets AZOR-1,0 Tablets SCHEDULING STATUS: S5 PROPRIETARY NAME (and dosage form): AZOR-0,25 Tablets AZOR-0,5 Tablets AZOR-1,0 Tablets COMPOSITION: Tablets containing 0,25 mg, 0,5 mg or 1,0 mg alprazolam . PHARMACOLOGICAL CLASSIFICATION: A 2.6 Tranquillizers PHARMACOLOGICAL ACTION: Alprazolam is a benzodiazepine with anxiolytic properties. It is rapidly absorbed from the gastro-intestinal tract following oral administration with peak plasma concentrations being achieved within 1 to 2 hours of a dose. The half-life of alprazolam in plasma is 12 to 15 hours and it is 70 to 80% bound to plasma protein. Alprazolam is metabolised chiefly in the liver and excreted in the urine as unchanged drug and metabolites. INDICATIONS: Anxiety disorders. Alprazolam is also used in the treatment of anxiety associated with depression. The effectiveness of alprazolam in the treatment of anxiety disorders and anxiety associated with depression for long term use exceeding six months has not been established. The doctor should periodically re-assess the usefulness of alprazolam for the individual patient. CONTRA-INDICATIONS: Alprazolam is contra-indicated in patients with porphyria and in patients with known hypersensitivity to benzodiazepines. It should be avoided in patients with pre-existing central nervous system depression or coma, acute pulmonary insufficiency or sleep apnoea. It should be used with care in patients with chronic pulmonary insufficiency. Do not administer during pregnancy or lactation. Use of alprazolam in the first trimester of pregnancy has been associated with various congenital malformations in the infant, but no clear relationship has been established. Administration of alprazolam in late pregnancy has been associated with intoxication of the neonate. Alprazol Leer el documento completo